This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: August 22, 2012
Last updated: May 20, 2013
Last verified: March 2013
This is a single-center, open-label, randomized crossover study being conducted in three cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of three cohorts (approximately 12 subjects per cohort) and they will receive both a single dose of E2006 in capsule formulation and a single dose of E2006 in tablet formulation, in random sequence, at a 1:1 ratio. The doses to be tested will be 2.5 mg, 10 mg, and 25 mg.

Condition Intervention Phase
Insomnia Drug: E2006 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Open-label, Randomized, Multi-cohort, Crossover Study of Relative Bioavailability of Tablet Versus Capsule Formulation of E2006 in Healthy Adult Subjects

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Plasma concentrations of E2006 of tablet vs. capsule formulations [ Time Frame: up to 336 hours post-dose ]

Secondary Outcome Measures:
  • Incidence of adverse events (AEs) [ Time Frame: 36 days ]

Enrollment: 40
Study Start Date: August 2012
Study Completion Date: December 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
E2006 2.5 mg Drug: E2006
2.5 mg, 10 mg, and 25 mg E2006 tablets
E2006 10mg Drug: E2006
2.5 mg, 10 mg, and 25 mg E2006 tablets
E2006 25 mg Drug: E2006
2.5 mg, 10 mg, and 25 mg E2006 tablets


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • Healthy males or females,
  • ages 18 to 55 years
  • Body mass index (BMI) >
  • 18 and 32 kg/m2 at Screening


  • Female subjects who are nursing
  • Subjects with a history of gastrointestinal surgery (hepatectomy, nephrectomy, digestive organ resection, etc.) that may affect PK profiles of E2006
  • Subjects with a known history of clinically significant drug or food allergies
  • Subjects with a known allergy or hypersensitivity to capsule or tablet ingredients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01673880

United States, Texas
PPD Development, LLC
Austin, Texas, United States, 78704
Sponsors and Collaborators
Eisai Inc.
Principal Investigator: Aziz Laurent PPD
  More Information

Responsible Party: Eisai Inc. Identifier: NCT01673880     History of Changes
Other Study ID Numbers: E2006-A001-005
Study First Received: August 22, 2012
Last Updated: May 20, 2013 processed this record on August 22, 2017